 | • レポートコード：MRC2303B040 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界のタンパク質結晶化市場規模が予測期間中（2022～2027年）に年平均8.1％上昇すると推測されています。本調査書では、タンパク質結晶化の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、技術別（X線結晶構造解析、NMR（核磁気共鳴）スペクトル、その他）分析、製品別（器具、試薬・消耗品、サービス・ソフトウェア）分析、エンドユーザー別（医薬品・バイオテクノロジー産業、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Rigaku Corporation、Hampton Research Corp、MiteGen LLC、Agilent Technologies Inc.、Krackeler Scientific Inc.、SARomics Biostructures AB、Tecan Trading AG、Charles River Laboratories International, Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のタンパク質結晶化市場規模：技術別 - X線結晶構造解析法タンパク質結晶化の市場規模 - NMR（核磁気共鳴）スペクトル法タンパク質結晶化の市場規模 - その他タンパク質結晶化の市場規模 ・世界のタンパク質結晶化市場規模：製品別 - 器具の市場規模 - 試薬・消耗品の市場規模 - サービス・ソフトウェアの市場規模 ・世界のタンパク質結晶化市場規模：エンドユーザー別 - 医薬品・バイオテクノロジー産業における市場規模 - その他エンドユーザーにおける市場規模 ・世界のタンパク質結晶化市場規模：地域別 - 北米のタンパク質結晶化市場規模 アメリカのタンパク質結晶化市場規模 カナダのタンパク質結晶化市場規模 メキシコのタンパク質結晶化市場規模 … - ヨーロッパのタンパク質結晶化市場規模 ドイツのタンパク質結晶化市場規模 イギリスのタンパク質結晶化市場規模 フランスのタンパク質結晶化市場規模 … - アジア太平洋のタンパク質結晶化市場規模 中国のタンパク質結晶化市場規模 日本のタンパク質結晶化市場規模 インドのタンパク質結晶化市場規模 … - 南米/中東のタンパク質結晶化市場規模 南アフリカのタンパク質結晶化市場規模 ブラジルのタンパク質結晶化市場規模 アルゼンチンのタンパク質結晶化市場規模 … ・競争状況 ・市場機会・将来動向 |
The Protein Crystallization Market is projected to register a CAGR of 8.1% during the forecast period (2022-2027).
COVID-19 had a significant impact on the growth of the protein crystallization market as, with the rise in cases of infectious diseases among the population, there was an increase in the demand for vaccines and protein-based therapies to overcome infection. The extensive use of protein crystallization to develop COVID-19 drugs has contributed to the market’s growth. For instance, in January 2021, Elasmogen identified protein-based drugs that can potentially stop COVID-19 infections through a partnership with the University of Minnesota. Thus, the agreement was signed between market players and the research institute with a focus on research for COVID-19 protein therapeutics, which created the need for protein crystallization. Thus, COVID-19 had a pronounced impact on the growth of the market.
The increasing demand for protein therapeutics is a key factor driving the market’s growth. This is because protein therapeutics have become an integral part of the health care industry over recent years. Protein therapeutics are extensively used to treat various major diseases, such as cancer, owing to their low immunogenicity and specificity. The increasing demand for protein-based drugs and therapeutics has led the manufacturers to implement growth strategies to gain the major market share, thereby increasing the market’s growth. For instance, in January 2022, Amgen entered into a partnership with Generate Biomedicines to discover and create protein therapeutics for five targets across several therapeutic areas and multiple modalities. Such research and development activities create the need for protein crystallization products and services and thus drive the growth of the market.
Furthermore, the increasing demand for protein therapeutics is due to the increasing prevalence of chronic disease and rising awareness regarding protein therapeutics’ efficiency. According to the World Health Organization (WHO) December 2020 article, an estimated 19.3 million new cancer cases were diagnosed worldwide. Such an increase in chronic disease prevalence creates a need to develop novel and efficient drugs, and as protein crystallization is widely used in drug discovery and development, it is expected to propel the growth of the market.
Advancements in protein crystallography and the implementation of standard protocols create a lucrative opportunity for market growth. Increasing application fields and areas of protein crystallization for tailoring effective drug candidates contribute to the market’s growth over the forecast period. Additionally, the strategic collaboration among the market players is also expected to boost the growth of the market. For instance, in March 2020, Intabio, Inc. and Protein Metrics, Inc., developers of advanced analytical tools for accelerating biopharmaceutical development and manufacturing, signed a co-development and co-marketing agreement to couple Intabio’s Blaze instrument system with the Byos software suite from Protein Metrics. The integrated Blaze-Byos platform helps to address a critical bottleneck for biopharmaceutical developers by automating the analysis of large protein structure/quality data sets to confirm product consistency and quality.
Thus, owing to the abovementioned factors, the market is expected to show positive growth over the forecast period. However, the lack of skilled professionals and the high cost of instruments may impede the growth of the market.
Protein Crystallization Market Trends
The Pharmaceuticals and Biotechnology Industries Segment is Expected to Hold a Major Market Share in the Protein Crystallization Market Marke
The pharmaceutical and biotechnology industries are expected to be the most lucrative segment, with extensive usage of protein crystallization in the production process. The pharmaceutical industry is expected to register significant revenue growth over the forecast period owing to the increasing application of protein crystallization in the drug discovery and development process and rising demand for protein therapeutics.
The increasing innovative product launches to meet the growing demand are also expected to boost the market segment’s growth. For instance, in July 2021, DeepMind signed a partnership with the European Molecular Biology Laboratory (EMBL) to create the most complete and accurate database of predicted protein structure models for the human proteome. The partnership aims to cover all ~20,000 proteins expressed by the human genome, and this data is to be freely and openly available to the scientific community. Additionally, in November 2020, Rigaku Corporation launched the Rigaky HyPix-Arc 100, a curved photon-counting X-ray detector for single crystal X-ray diffraction applications. Such launches are propelling the growth of the market segment.
Furthermore, the growing expansion of facilities by pharmaceutical and biotechnological companies to meet the increasing demand for protein crystallization is also boosting the growth of the segment. For instance, in March 2022, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, announced a EUR 5 million investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourney Biologics S.A. Such initiatives taken by the market players are propelling the growth of the market segment.
Thus, owing to the abovementioned factors, the market segment is expected to project growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is likely to dominate the global market owing to technological innovations in protein crystallization and an increase in research and development activities in the biopharma sector. The robust growth of protein crystallization can be attributed to the increasing investment and funding activities for proteomics research and the development of structure-based drugs.
The increase in research and development activities and collaboration among the market players and research institutes contribute to the growth of the overall regional market. For instance, in January 2022, Cullinan Oncology Inc. entered into a collaboration agreement with the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) to develop novel small-molecule immune modulators. The multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor kinase 1 (HPK1), a key regulator of immune cell activation and a high-priority target in immune-oncology. Such research agreements create the need for these products for protein crystallization and thus are expected to propel market growth.
Furthermore, in October 2021, EQRx and Absci Corporation signed a partnership agreement to discover and develop next-generation protein-based drugs. As per the agreement, both organizations leverage Absci’s Drug Creation technology for discovery and development activities, along with EQRx’s clinical development expertise and commercial capabilities, to advance next-generation, protein-based therapeutics across multiple therapeutic areas, including oncology and immunology.
Thus, the market is expected to grow in the North American region over the forecast period due to the abovementioned factors.
Protein Crystallization Market Competitor Analysis
The protein crystallization market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some companies currently dominating the market are Rigaku Corporation, Hampton Research Corporation, SARomics Biostructures AB, Agilent Technologies Inc., Charles River Laboratories Inc., and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Investment in the Research and Development of Biopharmaceuticals
4.2.2 Rising Adaption of the Protein Therapeutics
4.3 Market Restraints
4.3.1 Lack of trained Personnel
4.3.2 High cost of the instruments
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Technology
5.1.1 X-ray Crystallography
5.1.2 NMR Spectroscopy
5.1.3 Others
5.2 By Product
5.2.1 Instruments
5.2.2 Reagents or Consumables
5.2.3 Services and software
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Industries
5.3.2 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Rigaku Corporation
6.1.2 Hampton Research Corp
6.1.3 MiteGen LLC
6.1.4 Agilent Technologies Inc.
6.1.5 Krackeler Scientific Inc.
6.1.6 SARomics Biostructures AB
6.1.7 Tecan Trading AG
6.1.8 Charles River Laboratories International, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
